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Abstract
Diffuse Lipomatosis is a dermatological lesion consisting of a poorly circumscribed, inﬁltrative overgrowth of mature adipose
tissue that usually affects the trunk and the extremities. The lesions in the Tuberous Sclerosis Complex (TSC) are usually hamartomatous in nature, but lesions arising from adipocytes are rare. There are only three previous reports of association of TSC
with diffuse lipomatosis. Herein we present a case series of diffuse lipomatosis in three subjects with TSC and proceed to review
the literature for any other reported cases. On the basis of the three index cases and identiﬁcation of three more cases in the
literature, we believe that there is an association of diffuse lipomatosis with TSC that has not been appreciated until now. We
believe that this association in some selected cases will serve to improve diagnosis, surveillance, and management..
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Introduction
Tuberous sclerosis complex (TSC) is a multisystem genetic disorder with variable clinical manifestations.1 Patients commonly
present with benign tumors of the skin, brain, kidney, lung, and
heart. Dermatological ﬁndings are divided into major and minor
features per the 2012 consensus guidelines and update.1,2 The
major features include hypomelanotic macules, angioﬁbromas,
ﬁbrous cephalic plaques, ungual ﬁbromas, and shagreen
patches. The minor criteria include “confetti” skin lesions,
dental enamel pits, and intraoral ﬁbromas. Nearly 100% of individuals affected by TSC have skin or dental ﬁndings easily
detectable on physical examination.2
Benign tumors, including lipoma, are present in individuals
with TSC, with renal angiomyolipoma being the most common.
Angiomyolipomas have also been previously reported in the
skin of individuals with and without TSC.3 Lipomas are rarely
reported in TSC in other parts of the body, including the liver,
myocardium and adrenal glands.2 These are usually described as
solitary well-circumscribed lesions that are readily amenable to
surgical treatment with a tendency for recurrence after resection.
We describe three individuals with TSC who present with
diffuse overgrowth of fatty tissue that resulted in lower limb
and lower back deformities. The fatty tissue overgrowth is

best described as diffuse lipomatosis. This ﬁnding has previously been described in three other patients with TSC.4-6

Methods
We describe three cases of diffuse lipomatosis associated with TSC.
A systematic literature review was then conducted via MEDLINE to
identify cases of lipomas associated with TSC.

Results
Three subjects (14-year-old, 13-year-old, and 11-year-old) were
found to have diffuse lipomatosis involving extremities and
lower back. The ﬁrst patient presented with disﬁguring recurrent
lipomatous lesions involving the right lower extremity, and the
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second patient presented with painless lipomatosis lesions
involving the left lower extremity, and the third patient presented
with discomforting recurrent lower back lipomatous lesions.
Three more case reports were identiﬁed in the existing literature.

Case Report
Patient 1
The ﬁrst patient is an eleven-year-old girl diagnosed
with tuberous sclerosis complex (TSC), focal structural
epilepsy, and migraines. She presented to neurology after an
unprovoked focal seizure involving her right arm. This prompted
a brain MRI that revealed multiple cortical tubers and subependymal nodules. Her genetic workup was negative for a TSC1
and TSC2 mutation, and there was no family history of TSC
or lipomatosis. Her epilepsy was well controlled with
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oxcarbazepine, and her migraines were well controlled with
daily magnesium supplementation. When she was ten years
old, her parents noticed that her right thigh seemed to be larger
than the left. This prompted an MRI of her lower extremities
(Figure 1) which demonstrated an increase in subcutaneous fat
that inﬁltrated the thigh musculature. She was evaluated by
plastic surgery and underwent liposuction of the right thigh.
Hematoxylin and eosin stains conﬁrmed mature adipose tissue,
suggestive of lipoma. No evidence of atypia or malignancy.
One year after the liposuction was done, her right thigh was
again noted to be enlarged. A repeat MRI of the lower extremities revealed a recurrence of the lipomatosis (Figure 1).

Patient 2
The second patient is a fourteen-year-old boy with a history
of TSC, a long-standing history of focal epilepsy, and large

Figure 1. (Patient #1): MRI lower extremity before and after liposuction showing axial and coronal T1 images. Axial and coronal T1 images
of the upper right thigh before (A) and after (B) liposuction shows persistent or recurrence of asymmetric prominence of the superﬁcial fatty
tissues within the lateral right thigh (short arrows). Similar fatty inﬁltration of the gluteus maximus and medius muscle (short arrows).
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Figure 2. (Patient #2): MRI lower extremity showing axial and coronal T1 images. Axial and coronal T1 images of the left upper thigh/
buttock region demonstrates asymmetric prominence of the superﬁcial fatty tissues with reticulation in the posteromedial left buttock region
(long arrows). No well-deﬁned mass or lipoma.

sub-ependymal giant cell astrocytomas stable on Everolimus.
His genetic workup revealed a pathogenic variant in TSC2. He
was diagnosed with TSC at around nine months of age
following a seizure, and his epilepsy remained well controlled
on oxcarbazepine. When he was thirteen years old, the
patient-reported a compressible soft tissue swelling in the left
mesial thigh region, which was bothering him and causing mild
deformity. He denied any pain and declined a surgical
intervention.
Initially, an ultrasound of the left lower extremity was done,
that showed a 7 cm compressible soft tissue fullness in the left
mesial thigh with the same echogenicity as normal adjacent fat.
Later an MRI of the Lower extremity was done that conﬁrmed
the diagnosis. It showed a smooth marginated asymmetric
ovoid prominence of the superﬁcial fat, grossly measuring 7.2
× 3.1 cm, representing an asymmetric fatty tissue proliferation
or lipomatous proliferation (Figure 2).

Patient 3
The third patient is a thirteen-year-old boy with a history of TSC,
focal structural epilepsy, ADHD, cortical tubers, cardiac rhabdomyomas, hypertension, and recurrent atypical lipoma on the
lower back s/p surgical excision × 2. He was diagnosed with
TSC at around two years of age following a seizure and met TS
clinical criteria, with no further genetic testing was done. His epilepsy was well controlled on oxcarbazepine monotherapy.
At six years of age, he was noted to have soft tissue swelling
on the lower back, slowly increasing in size over several months.
He denied any pain, but the swelling was bothering him, especially when he sleeps. Ultrasound of the back and subsequent
pathology s/p resection done at six and nine years of age
showed a bland appearing mature adipose tissue with no evidence

of increased cellularity, necrosis, atypia, or increase in mitotic
activity. MRI of the lumbar spine (pre-resection) showed a
large 12.1 cm × 10.7 cm × 3.0 cm diameter predominately fatty
soft tissue mass within the deep subcutaneous tissues along the
posterior aspect of the lumbar spine and sacrum from the lower
L2 to the S4 level. There were some atypical features with incomplete encapsulation (Figure 3). He underwent ﬁrst surgical excision at age six with recurrence in a couple of years, for which
another surgical resection was performed with no further recurrence since then.

Discussion
Diffuse lipomatosis is a clinical ﬁnding that has previously been
reported in patients with TSC.4-6 There are only three case
reports of diffuse lipomatosis in patients with TSC. The ﬁrst
case was described by Klein and Barr4 in 1986 and involved
the right lower extremity in a TSC patient. The lesion inﬁltrated
the muscle and recurred after wide excision. Later, Alcázar
et al5 also reported an incidental diffuse lipomatosis involving
the dorsal transthoracic region that presented with a spontaneous pneumothorax. In 2018, Mittal et al6 reported the case of
an adult man with diffuse lipomatosis of the right lower extremity that caused signiﬁcant deformity. Our case report describes
three more individuals with TSC who present with a diffuse
overgrowth of fatty tissue, best described as diffuse lipomatosis,
that resulted in lower limb and lower back deformities. The case
reported by Klein and Barr4 and Mittal et al6 had lower limb
involvement, like our ﬁrst two cases, whereas Alcázar et al5
reported dorsal transthoracic involvement, almost similar to
our third case.
The ﬁrst and third case we presented underwent surgical
resection of lipomatous inﬁltration with recurrence of the
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Figure 3. (Patient #3): MRI of the lumbar spine. Axial T1 and sagittal T1 images before liposuction shows large, partially encapsulated fatty
soft tissue mass (arrows) with in the deep subcutaneous tissues along the posterior aspect of the lumbar spine and sacrum extending from
Lower L2 to the S4 level.

lesions. Recurrence after excision was also reported by Klein
and Barr4 The indications for the resection were cosmetic and
interference with ambulation. Surgical removal via lipectomy
or liposuction is the best therapeutic approach for these types
of lesions. However, there is a high rate of postoperative
local recurrence, especially after liposuction7 that should be
carefully considered before proceeding with resection.
Diffuse lipomatosis, as reported here, is a rare condition
consisting of diffuse, nonlocalized overgrowth of adipose
tissue. Diffuse lipomatosis usually occurs in patients under
two years of age but may also occur in adolescents and
adults. It usually affects the trunk or a limb, but also the
head and neck. These lesions can grow to be quite large and
may cause compression of vital structures and impair function.8 The most frequently reported lipomatosis in children
is congenital inﬁltrating lipomatosis of the face,9 in which
the adipose proliferation is accompanied by a proliferation
of ﬁbrovascular tissue and nerves, unlike diffuse lipomatosis,
which involve subcutaneous tissue and muscle but not nerve.
Diffuse lipomatosis also needs to be differentiated from
“genetic syndromes with the localized accumulation of subcutaneous fatty tissues,10 where lesions unlike the index
cases have characteristic lipedema, symmetrical masses,
nodular, and are painful.
Diffuse lipomatosis can be suggested by imaging due to its
diffuse, inﬁltrative appearance, and lack of a deﬁned capsule.
Consistent with the nature of the lesions (mature fat cells),
the signal changes of T1, T2, and fat-saturated sequences are
similar to that of fat which helps in conﬁrming the diagnosis
whereas contrast is usually not necessary to establish the

diagnosis.11 However, it can also mimic other fat containing
lesions such as liposarcoma or inﬁltrating lipoma. Histologic
sampling may be needed to conﬁrm the diagnosis.
Discrete lipomas are reported in patients with TSC in other
parts of the body, such as the liver, heart, and adrenal
glands.2 Tresoldi et al12 reported the presence of myocardial
fatty foci in TSC and suggested that this may represent an indicator of multiorgan involvement. While angiomyolipomas have
previously been well reported in the skin of individuals with
TSC,3 the association of hepatic lipomas is rarely observed in
patients with tuberous sclerosis complex.12,13 While lipomas
are usually solitary, well-circumscribed lesions readily amenable to surgical treatment, diffuse lipomatosis associated with
TSC, similar to the index cases described herein, may represent
a variable presentation and is a separate entity from discrete
lipoma.
These isolated benign tumors (like diffuse lipomatosis) have
rarely been described in patients with TSC. In addition to the
three cases reported here, there are only three other cases
reported in the literature of TSC patients with diffuse lipomatosis, which are summarized in Table 1. It is currently unclear if
this is due to a lack of potential association or due to a lack of
awareness and under reporting of diffuse lipomatosis in the
TSC population. The protein products of TSC1 and TSC2
(tuberin and hamartin) regulate mTOR (mammalian target of
Rapamycin) serine/threonine protein kinase activity14,15
which is responsible for the pathogenesis of multiple hamartomas, including lipomatous inﬁltration. Mutations in other genes
like PIK3CA & AKT can also lead to abnormal expression of
the TSC1 and TSC2 gene products.15,16 Mutations in these
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Table 1. Summary of Relevant Clinical Studies Related with Diffuse Lipomatosis.
Clinical
studies

No of
patients

Age

Indication

Diagnostic
criteria

Mittal et al.
2017

1

24 years

progressive diffuse swelling of
the right lower limb

Met clinical
criteria

Klein
et al.1986
Alcázar et al.
1998

1

15 years

1

37 years

Recurrent lipomatous tumor of
the right lower limb
Diffuse lipomatosis with
pneumothorax

Met Clinical
criteria
Met Clinical
criteria

Ilyas et al.
2021

3

11 years
14
years
13
years

Patient #1 Recurrent diffuse
lipomatosis of the right lower
limb.
Patient #2- Diffuse
lipomatosis of the left lower
limb
Patient #3 Recurrent diffuse
lipomatosis of the lower back

Met Clinical
criteria
Met Clinical
criteria (TSC2)
Met Clinical
criteria

genes lead to the mTOR pathway activation, resulting in cell
growth, proliferation, angiogenesis, and tumor formation.17
Activation of the mTOR pathway might also inhibit lipolysis
and stimulate lipogenesis in adipocytes.16 As studied by
Chakrabarti et al16 in his in-vitro adipocyte model, this phenomenon might explain lipomatous inﬁltration in the TSC.
TSC can be diagnosed by molecular testing and/or meeting
the clinical criteria. TSC has striking phenotypic variabilities,
and molecular testing of the TSC1 and TSC2 genes yields a positive result for 75%-90% of TSC-affected individuals. Clinical
diagnostic criteria become important when sequencing fails to
identify a disease-causing variant in TSC1 or TSC2. Clinical criteria are also relevant in those where genetic testing is not available. Furthermore, a subset of the TSC population does not
meet diagnostic criteria through clinical diagnosis and is
labeled as possible TSC.2 In these clinical situations, the addition or modiﬁcation of the diagnostic criteria is of value. The
diagnostic criteria for TSC are updated every 5-10 years as
new data accumulate in the literature.18 While the association
of diffuse lipomatosis with TSC highlighted in these cases is
rare, it is nonetheless present in a minority of cases. The association of lipomatous inﬁltration with TSC is a clinical observation that merits further investigation, including genetic
conﬁrmation of the fatty tissue sampling. Awareness of this
association may not only encourage researcher to further
examine, but also bring to light previously unreported cases
that will improve diagnosis, surveillance, and management.

Conclusions
Currently, lipomas in TSC occur in different organ systems and
appear as a component of angiolipoma. Given the case reports
described in this paper and several other previously reported
cases in the literature, diffuse lipomatosis may be associated
with TSC more often than previously thought. This possible

Diagnostic tool
Fine needle aspiration
cytology
MRI
Biopsy & Excision
x-ray
Biopsy
x-ray
Abdominal CT
Fine needle aspiration
cytology
x-ray & MRI
Ultrasound & MRI

Site
Lower limb

Lower limb
Dorsal transthoracic
involvement
Lower limb
Lower limb
Lower back

Ultrasound & MRI,
Biopsy and Excision

association needs further assessment and consideration. This
clinical ﬁnding could facilitate the diagnosis of TSC in some
challenging cases, particularly young individuals, allowing
earlier implementation of surveillance.
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